PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
20.86%
Revenue growth under 50% of CRON.TO's 81.89%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-21.47%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-27.53%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-27.53%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
686.38%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
671.43%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
669.28%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12852.71%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
5.64%
FCF growth under 50% of CRON.TO's 24.78%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1150.19%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-1150.19%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-11.55%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
2791.98%
Net income/share CAGR above 1.5x CRON.TO's 69.86% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
2791.98%
5Y net income/share CAGR above 1.5x CRON.TO's 69.86%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
4465.63%
3Y net income/share CAGR above 1.5x CRON.TO's 69.86%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1891.94%
10Y equity/share CAGR above 1.5x CRON.TO's 235.87%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
1891.94%
5Y equity/share CAGR above 1.5x CRON.TO's 235.87%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
4563.18%
3Y equity/share CAGR above 1.5x CRON.TO's 235.87%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.77%
AR growth well above CRON.TO's 121.58%. Michael Burry fears inflated revenue or higher default risk in the near future.
63.89%
Inventory growth well above CRON.TO's 8.33%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
11.84%
Asset growth well under 50% of CRON.TO's 35.17%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
13.20%
Under 50% of CRON.TO's 48.02%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
5.20%
Debt growth far above CRON.TO's 1.49%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
96.49%
R&D growth of 96.49% while CRON.TO is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
97.59%
SG&A growth well above CRON.TO's 25.36%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.